Now you can find the information you really need...

Evidence-Based Medicine

Editors: B Haynes & D Sackett

With 2 million new papers published each year how can you be sure you read all the papers essential for your daily practice, and how can you be sure of the scientific soundness of what you do read? One answer to this dilemma is practising evidence based medicine, basing clinical decisions on the best available scientific evidence.

To meet this need the BMJ Publishing Group together with the American College of Physicians is launching a new journal - Evidence - Based Medicine. This new journal is a development of the ACP Journal Club.


Published bi-monthly *Evidence - Based Medicine*, will survey a wide range of international medical journals (at least 70) to identify the key research papers that are scientifically valid and relevant to practice.











Launching in September 1995, Evidence-Based Medicine will:

- use scientific criteria to select the abstracts from the most important papers from the world's leading journals
- select only those papers which have a direct message for practice
- provide commentaries on the abstracts which will make clear the importance of the papers
- supply educational material to teach you about evidence based medicine
- cover all medical advances that are really important
- cover internal medicine, and the major specialties, including general surgery, paediatrics, obstetrics & gynaecology, psychiatry, general practice, anaesthesiology and ophthalmology.





AICIP

Annual Subscription Rate (Volume One, 7 issues - 1995-96) BMA Members Rate: £35, Personal Rate: £50, Institutional Rate: £80

Card No

BM Publishing J Group

Oraer rom

 Expry date:
Signature:
(Your signature is essential when paying by credit card)
Name.

AB Subscribes in Inflamentable of the Good observing procedules the compromise in New York that is a finite procedule of the Control of the C

Return to: BMJ Publishing Group, Journals Marketing Department, PO Box 299, London WC1H 9TD LK. Tel: 0171-383-6270. Fax: 0171-383-6402

PRESCRIBING

INFORMATION Presentations: Pulmicort Resputes. (2ml single dose unit ampoules) containing 0.25mg/ml or 0.5mg/ml budesonide in a suspension for nabulisation Uses: Bronchial asthma where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Dosage and administration: Dosage schedules Administer from suitable nebulisers Dose delivered to the patient varies depending on the nebulising equipment used (see data sheet). Adjust dosage individually. Initially during periods of severe asthma and while reducing or discontinuing oral glucocorticosteroids the recommended dose in adults tincluding elderly and children 12 years and older) is usually 1-2mg twice daily. In very severe cases the dosage may be further increased. Children 3 months to 12 years: 0.5-1mg twice daily. The maintenance dose should be the lowest dose which keeps the patient symptomfree. Recommended doses are: Adults tincluding elderly and children 12 years and older): 0.5-ling twice daily Children (3 months to 12 years): 0.25-0.5mg twice daily. For an increased theraneutic effect increase dose of Pulmicort rather than combine treatment with oral corticosteroids because of the lower risk of systemic effects. Contraindications, warnings, etc.: Contraindications: Hypersensitivity to any of the constituents. Special warnings and precautions: Care is needed in patients with pulmonary tuberculosis and viral infections in the airways. A short course of oral steroids in addition to Pulmicort may be required in patients with excessive mucus in the bronchi. Transfer of patients dependent on oral steroids to Pulmicort demands special care: see data sheet for further details. The nebuliser chamber should be cleaned and dried after every administration. Pulmicort does not affect the ability to drive and use machines. Pulmicort Respules can be mixed with 0.9% saline and with solutions of terbutaline, salbutamol, sodium cromoglycate or infatropium bromide. Side-effects: Mild irritation in the throat, coughing and hourseness and oral candidiasis have been reported. In rare cases inhaled drugs may provoke bronchoconstriction in hyperreactive nationts. Facial skin should be washed after use of the face mask as irritation can occur. Coughing can usually be prevented by inhaling a Ba-agonist (e.g terbutaline) 5-10 minutes before inhalation of Pulmicort Respules. Avoid in pregnancy. Pharmaceutical

Inspired control from their early months



Herts WD4 8DH

precautions: Store below 30 C. Use within 3 months of opening the foil envelope. Protect opened ampoule from light. Use within 12 hours of opening Legal status: POM. Basic NHS price: Pulmicort Resputes 0.25mg/ml (20 single dose units) £32.00. Pulmicort Resputes 0.5mg/ml (20 single dose units) £44.64. Product licence nos.: Pulmcort Respules 0.25mg/ml PI 0017/0309, Pulmicort Respules 0.5me/ml PL 0017/0310

Name and address of Product Licence holder: Astra Pharmaceuticals Ltd.

® Registered Trademark Date of preparation: May 1995 P.Res. 0524



Nebulised Steroid Control